Corona Virus Disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2. Emerging genetic and clinical evidence suggests similarities between COVID-19 patients and those with severe acute respiratory syndrome and Middle East respiratory syndrome. Hematological changes such as lymphopenia and thrombocytopenia are not rare in COVID-19 patients, and a smaller population of these patients had leukopenia. Thrombocytopenia was detected in 5–41.7% of the patients with COVID-19. Analyzing the dynamic decrease in platelet counts may be useful in the prognosis of patients with COVID-19. However, the mechanisms underlying the development of thrombocytopenia remain to be elucidated. This review summarizes the hematological changes in patients infected with SARS-CoV-2 and possible underlying mechanisms of thrombocytopenia development. Highlights • Early diagnosis and treatment of COVID-19 patients can reduce mortality. • There is no laboratory test index to predict disease progression and prognosis. • Progressive decline in platelets may be a prognostic factor for COVID-19 patients. • Monitoring platelet count may be an effective index for COVID-19 progression.
【저자키워드】 COVID-19, SARS-CoV-2, thrombocytopenia,